EG24074A - Formulation - Google Patents
FormulationInfo
- Publication number
- EG24074A EG24074A EG20010017A EG20010017A EG24074A EG 24074 A EG24074 A EG 24074A EG 20010017 A EG20010017 A EG 20010017A EG 20010017 A EG20010017 A EG 20010017A EG 24074 A EG24074 A EG 24074A
- Authority
- EG
- Egypt
- Prior art keywords
- formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0000313.7A GB0000313D0 (en) | 2000-01-10 | 2000-01-10 | Formulation |
| GBGB0008837.7A GB0008837D0 (en) | 2000-01-10 | 2000-04-12 | Formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EG24074A true EG24074A (en) | 2008-05-11 |
Family
ID=26243352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EG20010017A EG24074A (en) | 2000-01-10 | 2001-01-08 | Formulation |
Country Status (41)
| Country | Link |
|---|---|
| US (5) | US20030125387A1 (fr) |
| EP (4) | EP2286818B1 (fr) |
| JP (3) | JP3713237B2 (fr) |
| KR (1) | KR100802366B1 (fr) |
| CN (1) | CN1222292C (fr) |
| AR (1) | AR027510A1 (fr) |
| AT (1) | ATE306928T1 (fr) |
| AU (1) | AU762080B2 (fr) |
| BE (1) | BE1013477A3 (fr) |
| BG (1) | BG65776B1 (fr) |
| BR (1) | BR0107445B1 (fr) |
| CA (1) | CA2351004C (fr) |
| CH (1) | CH696260A5 (fr) |
| CO (1) | CO5280206A1 (fr) |
| CY (1) | CY1116520T1 (fr) |
| CZ (1) | CZ304689B6 (fr) |
| DE (2) | DE60114145T3 (fr) |
| DK (2) | DK1250138T4 (fr) |
| EE (1) | EE05421B1 (fr) |
| EG (1) | EG24074A (fr) |
| ES (3) | ES2248272T5 (fr) |
| FR (1) | FR2803516B1 (fr) |
| GB (3) | GB0000313D0 (fr) |
| HK (3) | HK1049286B (fr) |
| HU (1) | HU230162B1 (fr) |
| IL (2) | IL150230A0 (fr) |
| IS (1) | IS2932B (fr) |
| IT (2) | ITTO20010005A1 (fr) |
| MX (1) | MXPA02006698A (fr) |
| MY (1) | MY118583A (fr) |
| NL (1) | NL1017075C2 (fr) |
| NO (2) | NO336286B1 (fr) |
| PL (1) | PL202525B1 (fr) |
| PT (2) | PT2266573E (fr) |
| RU (1) | RU2263507C9 (fr) |
| SI (2) | SI1250138T2 (fr) |
| SK (1) | SK287221B6 (fr) |
| TW (1) | TWI259086B (fr) |
| UA (1) | UA75879C2 (fr) |
| WO (1) | WO2001051056A1 (fr) |
| ZA (1) | ZA200204165B (fr) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| WO2003006064A1 (fr) * | 2001-07-07 | 2003-01-23 | Astrazeneca Ab | Formulation pharmaceutique pour l'administration intramusculaire de fulvestrant |
| KR101086533B1 (ko) | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
| TW200404552A (en) * | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
| US20050152858A1 (en) * | 2003-07-11 | 2005-07-14 | Isp Investments Inc. | Solubilizing agents for active or functional organic compounds |
| TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
| EP1623713A1 (fr) * | 2004-07-09 | 2006-02-08 | Proskelia SAS | Combinaisons d'antisetrogène et d'inhibteurs de l'aromatase |
| CA2604393A1 (fr) * | 2005-04-15 | 2006-10-26 | Schering Corporation | Methodes et compositions pour le traitement ou la prevention du cancer |
| JP2009509942A (ja) * | 2005-09-26 | 2009-03-12 | ホスピラ・オーストラリア・ピーティーワイ・リミテッド | フルベストラント製剤 |
| CN102014925B (zh) * | 2008-03-07 | 2013-02-06 | 赛多斯有限责任公司 | 氟维司群配制剂 |
| AU2014200332B2 (en) * | 2008-04-28 | 2016-10-06 | Diurnal Limited | Lipid composition |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
| WO2011159769A2 (fr) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Modulateurs de récepteur d'œstrogène d'indane et utilisations de ceux-ci |
| ES2784497T3 (es) | 2010-09-16 | 2020-09-28 | Shimoda Biotech Pty Ltd | Composiciones de fulvestrant y métodos de uso |
| MX2013013558A (es) | 2011-05-20 | 2013-12-16 | Capital Business Y Gestion De Finanzas S L | Composicion farmaceutica. |
| CN102391341B (zh) * | 2011-08-09 | 2013-05-22 | 福建省微生物研究所 | 制备6,7-脱氢-17β-烃酰氧基诺龙的方法 |
| CN103070871B (zh) * | 2011-10-26 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 一种氟维司群的药物组合物 |
| LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| WO2013090829A1 (fr) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Modulateurs des récepteurs des œstrogènes et ses utilisations |
| PE20150099A1 (es) | 2011-12-16 | 2015-01-30 | Olema Pharmaceuticals Inc | Compuestos novedosos de benzopirano, composiciones y usos de los mismos |
| CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
| CN102600073B (zh) * | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
| WO2013153559A1 (fr) * | 2012-04-09 | 2013-10-17 | Scidose, Llc | Formulations de fulvestrant |
| US11179468B2 (en) | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| JP6356218B2 (ja) | 2013-04-18 | 2018-07-11 | シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法 |
| US10392667B2 (en) | 2013-06-07 | 2019-08-27 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| WO2014203129A1 (fr) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinaisons de composés benzopyrane, leurs compositions et utilisations |
| WO2014203132A1 (fr) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Composés de benzopyran substitués, leurs compositions et utilisations |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| JP2016529308A (ja) * | 2013-09-06 | 2016-09-23 | サラー ウッディン アハメド， | フルベストラント組成物 |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| KR20160124909A (ko) | 2014-03-13 | 2016-10-28 | 에프. 호프만-라 로슈 아게 | 에스트로겐 수용체 조절제를 함유하는 치료 조합물 |
| AU2015264003A1 (en) | 2014-05-22 | 2016-11-17 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
| BR112017007662B1 (pt) | 2014-12-18 | 2021-11-03 | F. Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| UA122346C2 (uk) | 2015-10-01 | 2020-10-26 | Олема Фармасьютикалз, Інк. | ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ |
| CN108430454A (zh) | 2015-10-13 | 2018-08-21 | 西弥斯医疗有限公司 | 氟维司群组合物 |
| WO2017100715A1 (fr) | 2015-12-09 | 2017-06-15 | The Board Of Trustees Of The University Of Illinois | Composés régulateurs à la baisse des récepteurs des œstrogènes sélectifs à base de benzothiophène |
| WO2017173071A1 (fr) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Composition pharmaceutique d'hormone stéroïde |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| WO2017175810A1 (fr) | 2016-04-06 | 2017-10-12 | 富士フイルム株式会社 | Composition médicinale |
| US9969732B2 (en) | 2016-04-08 | 2018-05-15 | Genentech, Inc. | Tetrahydroisoquinoline estrogen receptor modulators and uses thereof |
| MX2018013414A (es) * | 2016-05-06 | 2019-06-06 | Eagle Pharmaceuticals Inc | Formulaciones de fulvestrant y metodos para su uso. |
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| WO2017208847A1 (fr) | 2016-05-31 | 2017-12-07 | 富士フイルム株式会社 | Préparation pharmaceutique |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| JP2019521983A (ja) | 2016-06-16 | 2019-08-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用 |
| WO2017216279A1 (fr) * | 2016-06-16 | 2017-12-21 | F. Hoffmann-La Roche Ag | Modulateurs des récepteurs des œstrogènes hétéroaryles et leurs utilisations |
| CN107789320B (zh) * | 2016-08-31 | 2021-06-22 | 鲁南制药集团股份有限公司 | 一种氟维司群缓释注射液及其制备工艺 |
| CA3073836A1 (fr) | 2017-09-11 | 2019-03-14 | Atossa Therapeutics, Inc. | Procedes pour la fabrication et l'utilisation d'endoxifene |
| KR102670293B1 (ko) * | 2017-11-08 | 2024-05-30 | 이글 파마슈티컬즈 인코포레이티드 | 풀베스트란트 제제 및 그의 사용 방법 |
| CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
| CN111465398A (zh) * | 2018-01-31 | 2020-07-28 | 富士胶片株式会社 | 注射用制剂的制造方法 |
| RU2684330C1 (ru) * | 2018-02-02 | 2019-04-08 | Закрытое Акционерное Общество "Биокад" | Композиции фулвестранта |
| JP7384903B2 (ja) | 2018-05-24 | 2023-11-21 | ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | フルベストラントのプロドラッグ |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN111035613A (zh) * | 2018-10-12 | 2020-04-21 | 江苏恒瑞医药股份有限公司 | 一种包含氟维司群的可注射的药物组合物及其制备方法 |
| US20210403495A1 (en) | 2018-11-01 | 2021-12-30 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3924055B1 (fr) | 2019-02-15 | 2024-04-03 | Novartis AG | Dérivés de 3-(1-oxoisoindoline-2-yl)pipéridine-2,6-dione substitués et leurs utilisations |
| KR20220017931A (ko) | 2019-05-20 | 2022-02-14 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| RU2722988C1 (ru) * | 2019-11-19 | 2020-06-05 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей |
| US20220370359A1 (en) * | 2019-12-11 | 2022-11-24 | Shanghai Bocimed Pharmaceutical Co., Ltd. | Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| EP4188549A1 (fr) | 2020-08-03 | 2023-06-07 | Novartis AG | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations |
| WO2022112942A2 (fr) | 2020-11-24 | 2022-06-02 | Novartis Ag | Anticorps anti-cd48, conjugués anticorps-médicament et leurs utilisations |
| WO2022115451A1 (fr) | 2020-11-24 | 2022-06-02 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de mcl-1 et procédés d'utilisation |
| CN117794929A (zh) | 2021-02-02 | 2024-03-29 | 法国施维雅药厂 | 选择性bcl-xl protac化合物及使用方法 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| KR20230094172A (ko) * | 2021-12-20 | 2023-06-27 | 주식회사 삼양홀딩스 | 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법 |
| WO2023225320A1 (fr) | 2022-05-20 | 2023-11-23 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées |
| AR129382A1 (es) | 2022-05-20 | 2024-08-21 | Novartis Ag | Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso |
| WO2024189481A1 (fr) | 2023-03-10 | 2024-09-19 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de panras et leurs procédés d'utilisation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB817241A (en) | 1957-08-21 | 1959-07-29 | Vismara Francesco Spa | Oily solutions for parenteral administration containing adreno-cortical hormones |
| FR6241E (fr) | 1905-04-19 | 1906-10-10 | Ktiengesellschaft | Système de refroidissement du piston des moteurs à explosions et des compresseurs |
| DE947335C (de) | 1954-10-19 | 1956-08-16 | Schering Ag | Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron |
| US2983649A (en) | 1957-10-15 | 1961-05-09 | Francesco Vismara Societa Per | Ricinoleic acid ester solutions of adreno-cortical hormones |
| GB1060632A (en) * | 1962-09-11 | 1967-03-08 | Olin Mathieson | Steroid compositions |
| US3164520A (en) * | 1962-10-29 | 1965-01-05 | Olin Mathieson | Injectable steroid compositions containing at least 75% benzyl benzoate |
| JPS4327327Y1 (fr) | 1965-01-07 | 1968-11-12 | ||
| NL151903B (nl) | 1965-03-24 | 1977-01-17 | Schering Ag | Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat. |
| USRE28690E (en) * | 1965-05-05 | 1976-01-20 | Schering Aktiengesellschaft | 17α-Ethinyl-18-methyl-19-nortestosterone esters |
| GB1207571A (en) * | 1967-01-13 | 1970-10-07 | Takeda Chemical Industries Ltd | Injectable composition |
| SU549118A1 (ru) | 1973-04-02 | 1977-03-05 | Способ синхронизации половой охоты у циклирующих свиноматок | |
| SU676284A1 (ru) | 1975-06-26 | 1979-07-30 | Научно-Исследовательский Институт Животноводства | Способ синхронизации половой охоты у самок домашних животных |
| DE2548413A1 (de) | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
| US4048310A (en) | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid formulation in form of lotion or cream |
| US4048309A (en) | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid ointment formulations |
| NL7711916A (nl) | 1977-10-29 | 1979-05-02 | Akzo Nv | Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden. |
| FI65914C (fi) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| DE3708942A1 (de) | 1987-03-18 | 1988-09-29 | Schering Ag | 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate |
| EP0310542B1 (fr) * | 1987-10-01 | 1994-06-08 | Schering Aktiengesellschaft | Composés antigestagéniques et anti-oestrogéniques pour le traitement des tumeurs dépendant des hormones |
| DE3733478A1 (de) | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
| JPH04327327A (ja) | 1991-04-25 | 1992-11-16 | Toyoda Gosei Co Ltd | スリーブとホースの加締め用ダイス |
| CN1102095A (zh) | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| ZA9510926B (en) * | 1994-12-23 | 1996-07-03 | Schering Ag | Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception |
| US20010006963A1 (en) | 1995-03-16 | 2001-07-05 | Ursula Lachnit-Fixson | Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women |
| DE19510861A1 (de) | 1995-03-16 | 1996-09-19 | Schering Ag | Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen |
| EP0760237A1 (fr) | 1995-08-30 | 1997-03-05 | Cipla Limited | Microémulsions huile-dans-l'eau |
| GB9525194D0 (en) * | 1995-12-12 | 1996-02-07 | Zeneca Ltd | Pharmaceutical composition |
| JPH09208496A (ja) * | 1996-01-30 | 1997-08-12 | Takeda Chem Ind Ltd | Ｌｈ−ｒｈ拮抗物質含有組成物 |
| DE19613972A1 (de) | 1996-04-09 | 1997-10-16 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl |
| GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| US5952338A (en) | 1996-07-05 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Agent for prophylaxis and treatment of disturbance of visual function |
| JPH10203982A (ja) * | 1996-07-05 | 1998-08-04 | Takeda Chem Ind Ltd | 視機能障害の予防・治療剤 |
| DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE19638045A1 (de) | 1996-09-18 | 1998-03-19 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen |
| JPH10152438A (ja) * | 1996-11-22 | 1998-06-09 | Takeda Chem Ind Ltd | １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物 |
| US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
| JPH11158200A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | ヒト成長ホルモン・亜鉛複合体及びその用途 |
| EA002497B1 (ru) | 1997-12-03 | 2002-06-27 | Мерк Энд Ко., Инк. | Инъекционные композиции пролонгированного действия, содержащие гидрогенизированное касторовое масло |
| WO2000059473A1 (fr) | 1999-04-01 | 2000-10-12 | Inex Pharmaceuticals Corp. | Traitement du lymphome et composition a cet effet |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| JP4327327B2 (ja) | 2000-04-03 | 2009-09-09 | ロボテック株式会社 | 固定スプレー揺動装置 |
| WO2003006064A1 (fr) | 2001-07-07 | 2003-01-23 | Astrazeneca Ab | Formulation pharmaceutique pour l'administration intramusculaire de fulvestrant |
| GB0912999D0 (en) | 2009-07-27 | 2009-09-02 | Astrazeneca Ab | Method-803 |
-
2000
- 2000-01-10 GB GBGB0000313.7A patent/GB0000313D0/en not_active Ceased
- 2000-04-12 GB GBGB0008837.7A patent/GB0008837D0/en not_active Ceased
-
2001
- 2001-01-08 WO PCT/GB2001/000049 patent/WO2001051056A1/fr active IP Right Grant
- 2001-01-08 EP EP10180661.0A patent/EP2286818B1/fr not_active Expired - Lifetime
- 2001-01-08 SI SI200130446T patent/SI1250138T2/sl unknown
- 2001-01-08 EP EP01900186.6A patent/EP1250138B2/fr not_active Expired - Lifetime
- 2001-01-08 IL IL15023001A patent/IL150230A0/xx active IP Right Grant
- 2001-01-08 CA CA002351004A patent/CA2351004C/fr not_active Expired - Fee Related
- 2001-01-08 CZ CZ2002-2384A patent/CZ304689B6/cs not_active IP Right Cessation
- 2001-01-08 EP EP05016921A patent/EP1669073A3/fr not_active Withdrawn
- 2001-01-08 RU RU2002121507A patent/RU2263507C9/ru active
- 2001-01-08 SI SI200131044T patent/SI2266573T1/sl unknown
- 2001-01-08 ES ES01900186.6T patent/ES2248272T5/es not_active Expired - Lifetime
- 2001-01-08 JP JP2001551480A patent/JP3713237B2/ja not_active Expired - Lifetime
- 2001-01-08 DE DE60114145.8T patent/DE60114145T3/de not_active Expired - Lifetime
- 2001-01-08 AU AU23863/01A patent/AU762080B2/en not_active Expired
- 2001-01-08 AT AT01900186T patent/ATE306928T1/de active
- 2001-01-08 SK SK984-2002A patent/SK287221B6/sk not_active IP Right Cessation
- 2001-01-08 GB GB0100407A patent/GB2359254B/en not_active Expired - Lifetime
- 2001-01-08 EP EP10180667.7A patent/EP2266573B1/fr not_active Expired - Lifetime
- 2001-01-08 KR KR1020027008855A patent/KR100802366B1/ko active IP Right Grant
- 2001-01-08 ES ES10180667.7T patent/ES2543384T3/es not_active Expired - Lifetime
- 2001-01-08 US US10/169,777 patent/US20030125387A1/en not_active Abandoned
- 2001-01-08 CN CNB018035469A patent/CN1222292C/zh not_active Ceased
- 2001-01-08 DK DK01900186.6T patent/DK1250138T4/en active
- 2001-01-08 MX MXPA02006698A patent/MXPA02006698A/es active IP Right Grant
- 2001-01-08 HU HU0204137A patent/HU230162B1/hu not_active IP Right Cessation
- 2001-01-08 EG EG20010017A patent/EG24074A/xx active
- 2001-01-08 PT PT101806677T patent/PT2266573E/pt unknown
- 2001-01-08 BR BRPI0107445-8A patent/BR0107445B1/pt active IP Right Grant
- 2001-01-08 EE EEP200200387A patent/EE05421B1/xx unknown
- 2001-01-08 PL PL356030A patent/PL202525B1/pl unknown
- 2001-01-08 DK DK10180667.7T patent/DK2266573T3/en active
- 2001-01-09 US US09/756,291 patent/US6774122B2/en not_active Expired - Lifetime
- 2001-01-09 BE BE2001/0021A patent/BE1013477A3/fr not_active IP Right Cessation
- 2001-01-09 IT IT000005A patent/ITTO20010005A1/it unknown
- 2001-01-09 PT PT102548A patent/PT102548A/pt not_active Application Discontinuation
- 2001-01-10 MY MYPI20010107A patent/MY118583A/en unknown
- 2001-01-10 CH CH00029/01A patent/CH696260A5/de not_active IP Right Cessation
- 2001-01-10 FR FR0100248A patent/FR2803516B1/fr not_active Expired - Lifetime
- 2001-01-10 NL NL1017075A patent/NL1017075C2/nl not_active IP Right Cessation
- 2001-01-10 CO CO01001317A patent/CO5280206A1/es not_active Application Discontinuation
- 2001-01-10 AR ARP010100100A patent/AR027510A1/es not_active Application Discontinuation
- 2001-01-10 ES ES200100057A patent/ES2186517B2/es not_active Expired - Fee Related
- 2001-01-10 IT IT2001TO000008A patent/ITTO20010008A1/it unknown
- 2001-01-10 TW TW090100514A patent/TWI259086B/zh active
- 2001-01-10 DE DE10100779A patent/DE10100779A1/de not_active Ceased
- 2001-08-01 UA UA2002086628A patent/UA75879C2/uk unknown
-
2002
- 2002-05-24 ZA ZA200204165A patent/ZA200204165B/xx unknown
- 2002-06-13 IL IL150230A patent/IL150230A/en unknown
- 2002-06-18 BG BG106833A patent/BG65776B1/bg unknown
- 2002-07-03 NO NO20023227A patent/NO336286B1/no not_active IP Right Cessation
- 2002-07-03 IS IS6454A patent/IS2932B/is unknown
-
2003
- 2003-02-28 HK HK03101532.0A patent/HK1049286B/zh not_active IP Right Cessation
- 2003-07-21 HK HK03105241.3A patent/HK1052884B/zh not_active IP Right Cessation
- 2003-10-23 JP JP2003362875A patent/JP2004107353A/ja not_active Ceased
-
2004
- 2004-06-22 US US10/872,784 patent/US7456160B2/en not_active Expired - Lifetime
-
2008
- 2008-10-15 US US12/285,887 patent/US8329680B2/en active Active
-
2011
- 2011-04-18 HK HK11103860.8A patent/HK1150021A1/xx not_active IP Right Cessation
- 2011-06-20 JP JP2011135962A patent/JP2011190275A/ja active Pending
-
2012
- 2012-09-04 US US13/602,667 patent/US8466139B2/en not_active Expired - Lifetime
-
2015
- 2015-06-08 NO NO20150741A patent/NO337329B1/no not_active IP Right Cessation
- 2015-07-22 CY CY20151100648T patent/CY1116520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2359254B (en) | Formulation | |
| GB0000891D0 (en) | Formulation | |
| EG24226A (en) | Formulation | |
| AU8420301A (en) | Use | |
| GB9905898D0 (en) | Controlled-dose formulation | |
| GB9902304D0 (en) | Formulation | |
| AU1495802A (en) | Fungicidal formulation | |
| GB0125492D0 (en) | Formulation | |
| GB9927614D0 (en) | Sterliant formulation | |
| GB0005070D0 (en) | Use | |
| HK1054508A1 (zh) | 新型製劑 | |
| GB2375048B (en) | Formulation | |
| GB2396812B (en) | Formulation | |
| GB0116619D0 (en) | Formulation | |
| GB0004124D0 (en) | Formulation | |
| GB0007112D0 (en) | Formulation | |
| GB0010846D0 (en) | Formulation | |
| GB0001144D0 (en) | Glysophosate formulation | |
| GB0023069D0 (en) | Formulation | |
| GB0112497D0 (en) | Formulation | |
| GB9902236D0 (en) | Formulation | |
| GB0022027D0 (en) | Disfectant formulations | |
| GB9908776D0 (en) | Formulation | |
| GB9902089D0 (en) | Formulation | |
| GB9923538D0 (en) | Formulation |